Guggenheim Downgrades Spruce Biosciences to Neutral
Portfolio Pulse from Benzinga Newsdesk
Guggenheim analyst Evan Wang downgraded Spruce Biosciences (NASDAQ:SPRB) from Buy to Neutral, indicating a change in the investment firm's outlook on the company.

March 14, 2024 | 12:38 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Spruce Biosciences was downgraded from Buy to Neutral by Guggenheim analyst Evan Wang, potentially affecting investor sentiment.
Analyst ratings can significantly influence investor sentiment and stock prices in the short term. A downgrade from Buy to Neutral suggests a less optimistic outlook on the company's future performance, which could lead to a decrease in stock price as investors adjust their expectations.
CONFIDENCE 90
IMPORTANCE 75
RELEVANCE 100